In silico small molecule discovery Sales Target gene Discover hit Hit to lead Optimise lead Clinical Target gene identified with a viable assay High throughput.

Slides:



Advertisements
Similar presentations
Design of high-content and focused libraries to improve the development of new active compounds in the framework of the rational drug discovery Design.
Advertisements

Protein Structure.
FRAGMENT- BASED DRUG DESIGN Yemane Mengistu Michigan State University January 30, 2008.
Analysis of High-Throughput Screening Data C371 Fall 2004.
Christopher Reynolds Supervisor: Prof. Michael Sternberg Bioinformatics Department Division of Molecular Biosciences Imperial College London.
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Lipinski’s rule of five
Establishing a Successful Virtual Screening Process Stephen Pickett Roche Discovery Welwyn.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul.
Computational Molecular Biology (Spring’03) Chitta Baral Professor of Computer Science & Engg.
Summary Protein design seeks to find amino acid sequences which stably fold into specific 3-D structures. Modeling the inherent flexibility of the protein.
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
Active Learning Strategies for Drug Screening 1. Introduction At the intersection of drug discovery and experimental design, active learning algorithms.
Super fast identification and optimization of high quality drug candidates.
1111 Discovery Novel Allosteric Fragment Inhibitors of HIV-1 Reverse Transcriptase for HIV Prevention A/Prof Gilda Tachedjian Retroviral Biology and Antivirals.
In Silico Design of Selective Estrogen Receptor Modulators from Triazoles and Imines Joey Salisbury Dr. John C. Williams Small Molecules/Large Molecules.
Chemoinformatics in Drug Design
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Important Points in Drug Design based on Bioinformatics Tools History of Drug/Vaccine development –Plants or Natural Product Plant and Natural products.
GGAGATTCTGGGCCACTTTGGTTCCCCATGAGCCAAGACGGCACTTCTAATTTGCATTCCCTACCGGAGTCCCTGTCTGTAGCCAGCCTGGCTTTCAGCTGGTGCCCAAAGTGACAAATGTATCTGCAATGACAAAGGTAC CCTGGAAGGGCTCGCCCTCTGCGGAATTTCAGTTCATGCAGGCCTTGGTGCTTCCACATCTGTCCAAGGGCCTTTCAAATGTGACTTTTAACTCTGTGGATTGATTTGCCCGG
Homology Modeling David Shiuan Department of Life Science and Institute of Biotechnology National Dong Hwa University.
Protein Tertiary Structure Prediction
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
Christopher Reynolds, Stephen Muggleton and Michael Sternberg Bioinformatics and Computing Departments Imperial College London.
Rational Drug Design Soma Mandal, Mee'nal Moudgil, Sanat K. Mandal.
Practical session 2b Introduction to 3D Modelling and threading 9:30am-10:00am 3D modeling and threading 10:00am-10:30am Analysis of mutations in MYH6.
Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
EXPLORING CHEMICAL SPACE FOR DRUG DISCOVERY Daniel Svozil Laboratory of Informatics and Chemistry.
Fast Search Protein Structure Prediction Algorithm for Almost Perfect Matches1 By Jayakumar Rudhrasenan S Primary Supervisor: Prof. Heiko Schroder.
Faculté de Chimie, ULP, Strasbourg, FRANCE
Helen M. Berman, Rutgers University EMBO Practical Course Section: Searching Structure Databases September 26, 2008 PSI Structural Genomics Knowledgebase.
Use of Machine Learning in Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
Drug Discovery Process Massimiliano Beltramo, PhD.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Page 1 SCAI Dr. Marc Zimmermann Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Grid-enabled drug discovery.
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Structural proteomics
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Genomics II: The Proteome Using high-throughput methods to identify proteins and to understand their function.
Rational Drug Design Dr Robert Sbaglia. Curriculum Vitae Bachelor of Science (Honours), University of Melbourne Bachelor of Science.
JAK type I cytokine receptor YYYYYY YYYYYY Y Y JAK kinase extracellular intracellular JAK-STAT signalling.
Structural proteomics Handouts. Proteomics section from book already assigned.
Computer-aided drug discovery (CADD)/design methods have played a major role in the development of therapeutically important small molecules for several.
Feature Extraction Artificial Intelligence Research Laboratory Bioinformatics and Computational Biology Program Computational Intelligence, Learning, and.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
PubChem: An Open Repository for Chemical Structure and Biological Activity Information Steve Bryant The NIH Biowulf Cluster: 10 Years of Scientific Supercomputing.
Use of Machine Learning in Chemoinformatics
Discovery of Therapeutics to Improve Quality of Life Ram Samudrala University of Washington.
A truly integrated drug discovery company 26 th April 2016 CONFIDENTIAL.
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
Docking and Virtual Screening Using the BMI cluster
Molecular Modeling in Drug Discovery: an Overview
Natural products from plants
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
Christopher Reynolds Supervisor: Prof. Michael J.E. Sternberg
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Important Points in Drug Design based on Bioinformatics Tools
Ligand-Based Structural Hypotheses for Virtual Screening
Predicting Active Site Residue Annotations in the Pfam Database
“Structure Based Drug Design for Antidiabetics”
Università degli Studi di Milano
Important Points in Drug Design based on Bioinformatics Tools
Research Rational Drug Design: A process for drug design which bases the design of the drug upon the structure of its protein target. Structural mapping.
Julia Salas Case Study, CS379a
Presentation transcript:

in silico small molecule discovery Sales Target gene Discover hit Hit to lead Optimise lead Clinical Target gene identified with a viable assay High throughput screen in silico

Case 1 – receptor structure known Novel in silico hits ~ 100 Computer Database of Molecules 100,000 + dock molecules into receptor Secondary assay ? hits IC 50 < 10 µM

How successful is this method? From Shoichet’s group on target – protein tyrosine phosphate 1B None of the in silico hits found by HTS But unpredictable - other systems yielding < 1% MethodCompounds tested Hits with IC 50 < 10µ MHit rate High throughput screening (HTS) 400, % In silico docking365 from docking 185%

How does one get the receptor structure? X-ray structure available already at RCSB databank Set up a structure determination Predict structure

CloningRecombinant protein Expression Protein purification – mg quantities Protein crystalsElectron density map X-ray diffraction patternProtein structure Crystallization X-ray crystallography pipeline

Prediction protein structure by homology Query sequence Matched fold Match sequence against library of known folds

Phyre- Phyre and predecessor 3DPSSM > 1,000 citations

Case 2: Ligand activity data available Novel in silico hits database Observed activity Structure- activity rules Screen

INDDEx TM – A logic-based method Muggleton & Sternberg developed a logic-based strategy Method now incorporated into INDDEx within an Imperial spin-out Equinox Pharma INDDEx designed to exploit availability of active and inactive data on a at least c. 5 but ideally more ligands

Logic-rules lead to new chemotypes C D 7Å7Å A BB C Fragment B is bonded to fragment C Fragment C is bonded to fragment D A B C D 7Å7Å INDDEx can learn complex rule from simpler facts  Fragment A is 7Å from fragment B which is bonded to fragment C which is bonded to fragment D Fragment A is 7Å from fragment B

Rules can be understood by chemists Standard programs: Activity = 0.45 LogP Lumo V A B C D 7Å7Å ILP rule: In an active molecule: Fragment A is 7Å from fragment B which is bonded to fragment C which is bonded to fragment D  

Chemistrt a Blind trial of hit discovery on GPCR-1 Data from literature 250 novel in silico hits Order Observed activity - From Literature 157 Compounds 30 Verified in vitro hits NEW CHEMOTYPES Test Cerep in silico at Equinox Equinox outsourced wet chemistry and biology INDDEx

GPCR-1: training set Distribution of 686 training molecules collected from public domain Actives Inactives

GPCR Target 1 hits for optimatisation 4.7M molecules in Zinc database 400,000 drug like molecules 500 in silico hits 250 hits & new chemotypes 157 tested for inhibition 76 actives 39 for IC50 30 confirmed 30 chemotypes 30

GPCR-1: results of primary screening Number of in silico hits: 157 (10µM concentration) Number of actives: 76 Number of inactives: 81 Primary screen success rate = 48% True hits False hits

GPCR-1 results: IC 50 Number of hits sent for IC50: 39 Number with IC 50 < 12 µM = 30

GPCR-1: new chemotypes Distribution of hits based on their diversity (Tanimoto coefficients) New chemotype

Chemistrt a INDDEx Equinox hit discovery on GPCR-2 - Data from BioPrint (Cerep) 250 novel in silico hits Order Observed activity - From BioPrint 94 Compounds 28 Verified in vitro hits Test Cerep in silico at Equinox Equinox outsources wet chemistry and biology

Confirmed hit rate of in silico predictions on secondary screen c. 35% Target 1Target 2 In silco hits Primary screen hits (>30% binding at 10µM) No. compounds tested for IC IC50 results (<12µM) Estimated secondary hits if all primary hits tested 4042 Estimated hit rate = estimated secondary hits In silico hits 38/157 = 24 % 42 /94 = 45 %

Comparative hit rates Company / approachTarget Hit Rate Technology INDDExGPCR 1 & 2 + unknown target 35 % Ligand-based Structure-basedMultiple targets Average < 2% Docking into 3D structure High throughputMultiple targets Average 0.001% Experimental screening

Concluding remarks If protein structure available can initiative an in silico screening approach to find hits. –Success rate generally <.2% –X-ray structure determination requires mgs of material –Prediction of structure if sequence identity > 50% If structure- activity data available then in silico methods can yield far better hit rates c. 35% in silco methods complement high throughput and can find different hits

In silico small molecule discovery Michael Sternberg, Ata Amini, Paul Freemont & Michael Sternberg Imperial Collge Lond – & –